Johnson & Johnson stock edges higher as analysts lift long-term earnings outlook
Published on 09/21/2026 at 13:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Johnson & Johnson stock (ISIN US4781601046) is trading around USD 269 on the New York Stock Exchange with a market capitalization of about USD 650.65 billion as of September 20, 2026, reflecting the group’s status as a defensive healthcare heavyweight for long?term investors.
Analysts lift long?term earnings outlook
According to MarketBeat on September 21, 2026, Erste Group Bank increased its forecast for Johnson & Johnson’s earnings per share in fiscal year 2027 to USD 12.83, up slightly from a previous estimate of USD 12.81 and clearly above the current consensus estimate of USD 11.61 per share for that year.
In the same overview, Johnson & Johnson is described as carrying a consensus rating of Moderate Buy, with one analyst rating the shares Strong Buy, eighteen at Buy and six at Hold, and an average price target of USD 274.13, indicating a modest upside of about 1.5 percent from a share price level of roughly USD 269.97 mentioned in that report.MarketBeat
Latest reported quarterly figures
For investors, the most recent reported quarter is a key reference point. As of September 20, 2026, data compiled by Yahoo Finance show that Johnson & Johnson generated revenue of USD 25.31 billion and earnings of USD 5.53 billion in its second quarter of fiscal year 2026, implying a profit margin of about 21.86 percent for that period.
The same source indicates that second?quarter 2026 earnings per share came in at USD 2.90, slightly above an estimate of USD 2.85 and ahead of the prior?year quarter’s EPS of USD 2.77, meaning EPS increased by about 4.7 percent year on year while still beating consensus expectations by roughly 1.8 percent.Public.com
Scale and profitability remain central strengths
On a trailing twelve?month basis, Johnson & Johnson’s revenue stands at USD 97.93 billion and net income attributable to common shareholders at about USD 21.04 billion, corresponding to a profit margin around 21.48 percent according to figures compiled by Yahoo Finance.
The same data set points to a return on equity of 25.74 percent and a return on assets of 8.60 percent on a trailing basis, underlining that, despite its large scale, Johnson & Johnson continues to convert its global healthcare portfolio into double?digit profitability and solid capital efficiency.Yahoo Finance
Dividend and upcoming earnings date
Johnson & Johnson also remains a dividend payer. As of September 20, 2026, the forward dividend is indicated at USD 5.36 per share, equivalent to a yield of about 1.99 percent on a share price around USD 270, offering investors a combination of income and potential capital appreciation according to Yahoo Finance.
The same overview lists October 13, 2026 as the next scheduled earnings date, giving the market a clear timetable for the next update on revenue growth, margins and guidance, which will be scrutinized in light of the raised long?term EPS estimates and the current valuation.Yahoo Finance
Stock price, range and market metrics
Per price data cited by MarketBeat, shares of Johnson & Johnson opened at around USD 269.97 at the start of the latest trading session referenced there in September 2026. A separate snapshot from Yahoo Finance shows the stock at USD 269.99 at the close on September 18, 2026 on the NYSE, down 0.09 percent from a previous close of USD 270.22.
Additional trading metrics from Robinhood for the trading session on September 20, 2026 indicate a current price around USD 269.54, with an intraday high of USD 272.09 and a low of USD 267.20 and a reported volume of 16.09 million shares versus an average volume of 6.61 million, suggesting heightened trading activity around the stock compared with typical levels.
Key data on Johnson & Johnson stock
- Company: Johnson & Johnson
- ISIN: US4781601046
- Ticker: JNJ
- Trading venue: NYSE
- Price (as of September 18, 2026, 4:00 PM): 269.99 USD
- Market capitalization: 650.65 billion USD (as of September 20, 2026)
- Sector / Industry: Health Care / Pharmaceuticals and Medical Devices
- Index membership: S&P 500
- Next earnings date: October 13, 2026
